Particle.news
Health ❯ Healthcare ❯ Patient Care
Progression-Free Survival Response Rates Side Effects Adverse Effects Long-term Outcomes Clinical Outcomes Quality of Life Survival Rates Side Effects Management Clinical Trials Safety Profiles Adverse Events Drug Safety Toxicity Management Cognitive Decline Patient Satisfaction Safety and Tolerability Mortality Rates Patient Outcomes Research Methodology Weight Maintenance Immunotherapy Drug-free Remission Novel Interventions Long-term Follow-up Migraine Relief Eltrombopag Hair Growth Solutions Quality of Life Improvements Targeted Therapies Chemotherapy Resistance Asthma Management Overall Survival Patient Preferences Patient Selection Therapeutic Interventions Vaccine Development Alopecia Areata Therapeutic Innovations Bispecific Antibodies AI Recommendations Risks and Benefits Event-Free Survival Survival Outcomes Safety Profile Survey Results Intratumoral Therapies Motor Symptoms Exacerbation Rates Biomarkers in ALS Medication Management Chemotherapy and Radiotherapy Adjuvant Therapy Long-term Monitoring Minimal Residual Disease Comparative Effectiveness PASI Response Rates Hair Loss Treatments Symptom Improvement Invasive Disease-Free Survival Patient-Reported Outcomes Remission Rates Drug Side Effects Drug Combinations Amyloid Plaques Radiographic Progression-Free Survival Monotherapy Medication Tolerability
Early phase 2 results show the drug kept about half of lost lean mass without reducing overall weight loss; larger and longer trials are needed before it could be used in patients.
